Table 1. Clinically available non-invasive screening method with stool DNA detection for colorectal cancer diagnosis

Product name	Target	Sensitivity, cancer	Specificity, cancer	Sensitivity, advanced adenoma detection
Cologuard [8]	NDRG4, BMP3 DNA methylation, KRAS mutation, hemoglobin	92.3%	89.8%	42.4%
EarlyTect [10]	SDT2 methylation, hemoglobin	90.2%	90.2%	66.7%

NDRG4, N-myc downstream-regulated gene 4; BMP3, bone morphogenetic protein 3; KRAS, Kirsten rat sarcoma virus; SDT2, synthecan 2.